{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:43:20Z","timestamp":1790462600679,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81503359"],"award-info":[{"award-number":["81503359"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jiph.2020.07.004","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T07:25:06Z","timestamp":1594625106000},"page":"1405-1414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics"],"prefix":"10.1016","volume":"13","author":[{"given":"Dongyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zigang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2020.07.004_bib0005","unstructured":"Real-time big data reporting of novel coronavirus pneumonia outbreaks from Baidu. https:\/\/voice.baidu.com\/act\/newpneumonia\/newpneumonia\/?from=osari_aladin_top1#tab4."},{"issue":"5","key":"10.1016\/j.jiph.2020.07.004_bib0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.jiph.2020.07.004_bib0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3181\/0903-MR-94","article-title":"Coronavirus diversity, phylogeny and interspecies jumping","volume":"234","author":"Woo","year":"2009","journal-title":"Exp Biol Med (Maywood)"},{"issue":"27","key":"10.1016\/j.jiph.2020.07.004_bib0020","first-page":"209","article-title":"Cultivation of the virus of infectious bronchitis of chickens in embryonated chicken eggs","volume":"8","author":"Cunningham","year":"1947","journal-title":"Am J Vet Res"},{"issue":"8","key":"10.1016\/j.jiph.2020.07.004_bib0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.07.004_bib0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fmicb.2019.00569","article-title":"Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections","volume":"10","author":"Skariyachan","year":"2019","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.jiph.2020.07.004_bib0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11684-017-0589-5","article-title":"Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses","volume":"11","author":"Wang","year":"2017","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.jiph.2020.07.004_bib0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jiph.2020.07.004_bib0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/978-0-387-33012-9_93","article-title":"Identification of ferret ACE2 and its receptor function for SARS-coronavirus","volume":"581","author":"Zamoto","year":"2006","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.jiph.2020.07.004_bib0050","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.jiph.2020.07.004_bib0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.antiviral.2013.09.028","article-title":"Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research","volume":"100","author":"Simmons","year":"2013","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.jiph.2020.07.004_bib0060","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of ebola virus RNA-Dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.jiph.2020.07.004_bib0065","first-page":"38","article-title":"Safety and efficacy of lopinavir\/ritonavir during pregnancy: a systematic review","volume":"15","author":"Pasley","year":"2013","journal-title":"AIDS Rev"},{"issue":"6489","key":"10.1016\/j.jiph.2020.07.004_bib0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jiph.2020.07.004_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antiviral Res"},{"issue":"24","key":"10.1016\/j.jiph.2020.07.004_bib0080","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"issue":"10236","key":"10.1016\/j.jiph.2020.07.004_bib0085","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jiph.2020.07.004_bib0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jiph.2020.07.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.jiph.2020.07.004_bib0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"10","key":"10.1016\/j.jiph.2020.07.004_bib0105","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.07.004_bib0110","first-page":"382","article-title":"Compassionate use of remdesivir in Covid-19. Reply","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jiph.2020.07.004_bib0115","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (Favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jiph.2020.07.004_bib0120","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.coviro.2011.10.030","article-title":"Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action","volume":"1","author":"Paeshuyse","year":"2011","journal-title":"Curr Opin Virol"},{"issue":"5","key":"10.1016\/j.jiph.2020.07.004_bib0125","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/thx.2003.014076","article-title":"Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak","volume":"59","author":"Sung","year":"2004","journal-title":"Thorax"},{"issue":"21","key":"10.1016\/j.jiph.2020.07.004_bib0130","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1001\/jama.289.21.JOC30885","article-title":"Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area","volume":"289","author":"Booth","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2020.07.004_bib0135","series-title":"Guidelines for novel coronavirus pneumonia diagnosis and treatment scheme(Trial edition fifth)","author":"China NHCotPsRo","year":"2020"},{"issue":"5","key":"10.1016\/j.jiph.2020.07.004_bib0140","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.outlook.2003.07.002","article-title":"Severe acute respiratory syndrome (SARS) in Hong Kong: patients\u2019 experiences","volume":"51","author":"Tiwari","year":"2003","journal-title":"Nurs Outlook"},{"issue":"11","key":"10.1016\/j.jiph.2020.07.004_bib0145","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study","volume":"14","author":"Omrani","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2020.07.004_bib0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3851\/IMP2792","article-title":"Ribavirin and interferon-alpha2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases","volume":"20","author":"Khalid","year":"2015","journal-title":"Antivir Ther (Lond)"},{"issue":"2","key":"10.1016\/j.jiph.2020.07.004_bib0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3947\/ic.2016.48.2.118","article-title":"Clinical presentation and outcomes of middle east respiratory syndrome in the Republic of Korea","volume":"48","author":"Choi","year":"2016","journal-title":"Infect Chemother"},{"issue":"9","key":"10.1016\/j.jiph.2020.07.004_bib0160","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study","volume":"70","author":"Arabi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jiph.2020.07.004_bib0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"10.1016\/j.jiph.2020.07.004_bib0170","unstructured":"A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03394209."},{"key":"10.1016\/j.jiph.2020.07.004_bib0175","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"issue":"5","key":"10.1016\/j.jiph.2020.07.004_bib0180","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jiph.2020.07.004_bib0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jiph.2020.07.004_bib0190","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"issue":"8","key":"10.1016\/j.jiph.2020.07.004_bib0195","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jiph.2020.07.004_bib0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14787210.5.1.13","article-title":"Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections","volume":"5","author":"Tan","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jiph.2020.07.004_bib0205","article-title":"COVID-19: abnormal liver function tests","author":"Cai","year":"2020","journal-title":"J Hepatol"},{"issue":"20","key":"10.1016\/j.jiph.2020.07.004_bib0210","first-page":"30218","article-title":"Coronavirus disease 2019 and transplantation: a view from the inside","volume":"S0168-8278","author":"Gori","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jiph.2020.07.004_bib0215","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.15992","article-title":"Coronavirus disease 2019 and transplantation: The combination of lopinavir\/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome","author":"Xia","year":"2020","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.jiph.2020.07.004_bib0220","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jiph.2020.07.004_bib0225","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.jiph.2020.07.004_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jiph.2020.07.004_bib0235","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.07.004_bib0240","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jiph.2020.07.004_bib0245","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jiph.2020.07.004_bib0250","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jiph.2020.07.004_bib0255","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/10937404.2020.1752340","article-title":"Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review","volume":"23","author":"Pereira","year":"2020","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.jiph.2020.07.004_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.jiph.2020.07.004_bib0265","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiph.2020.07.004_bib0270","series-title":"Guidelines for novel coronavirus pneumonia diagnosis and treatment scheme (Trial edition sixth)","author":"China NHCotPsRo","year":"2020"},{"issue":"1","key":"10.1016\/j.jiph.2020.07.004_bib0275","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.jiph.2020.07.004_bib0280","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.jiph.2020.07.004_bib0285","first-page":"e208630","article-title":"Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2020.07.004_bib0290","doi-asserted-by":"crossref","first-page":"m1844","DOI":"10.1136\/bmj.m1844","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mahevas","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2020.07.004_bib0295","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jiph.2020.07.004_bib0300","doi-asserted-by":"crossref","first-page":"e1977","DOI":"10.1002\/rmv.1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis","volume":"28","author":"Morra","year":"2018","journal-title":"Rev Med Virol"},{"issue":"2","key":"10.1016\/j.jiph.2020.07.004_bib0305","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cytogfr.2014.10.006","article-title":"High efficiency targeting of IFN-alpha activity: possible applications in fighting tumours and infections","volume":"26","author":"Uze","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jiph.2020.07.004_bib0310","series-title":"Guidelines for novel coronavirus pneumonia diagnosis and treatment scheme (Trial edition seventh)","author":"China NHCotPsRo","year":"2020"},{"issue":"7","key":"10.1016\/j.jiph.2020.07.004_bib0315","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1089\/1079990041535610","article-title":"Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha\/beta) but not by type II interferon (IFN-gamma)","volume":"24","author":"Zheng","year":"2004","journal-title":"J Interferon Cytokine Res"},{"issue":"Pt 8","key":"10.1016\/j.jiph.2020.07.004_bib0320","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1099\/vir.0.052910-0","article-title":"MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment","volume":"94","author":"de Wilde","year":"2013","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.jiph.2020.07.004_bib0325","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.jiph.2020.07.004_bib0330","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","article-title":"Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study","volume":"290","author":"Loutfy","year":"2003","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.jiph.2020.07.004_bib0335","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"S0163-4453","author":"Zhu","year":"2020","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jiph.2020.07.004_bib0340","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures","volume":"53","author":"Khamitov","year":"2008","journal-title":"Vopr Virusol"},{"key":"10.1016\/j.jiph.2020.07.004_bib0345","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discov"},{"issue":"20","key":"10.1016\/j.jiph.2020.07.004_bib0350","article-title":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study","volume":"S1198-743X","author":"Lian","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2020.07.004_bib0355","article-title":"Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2020.07.004_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Runfeng","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jiph.2020.07.004_bib0365","first-page":"153242","article-title":"Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: a multicenter, prospective, randomized controlled trial","author":"Hu","year":"2020","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.jiph.2020.07.004_bib0370","first-page":"152","article-title":"Convalescent plasma: new evidence for an old therapeutic tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfus"},{"issue":"1","key":"10.1016\/j.jiph.2020.07.004_bib0375","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"16","key":"10.1016\/j.jiph.2020.07.004_bib0380","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jiph.2020.07.004_bib0385","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/stem.1681","article-title":"Concise review: the surface markers and identity of human mesenchymal stem cells","volume":"32","author":"Lv","year":"2014","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.jiph.2020.07.004_bib0390","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/thoraxjnl-2011-201176","article-title":"Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia","volume":"67","author":"Gupta","year":"2012","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jiph.2020.07.004_bib0395","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13287-016-0395-z","article-title":"Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice","volume":"7","author":"Li","year":"2016","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"10.1016\/j.jiph.2020.07.004_bib0400","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis"},{"key":"10.1016\/j.jiph.2020.07.004_bib0405","unstructured":"Draft landscape of COVID-19 candidate vaccines. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"10.1016\/j.jiph.2020.07.004_bib0410","series-title":"Moderna, moderna announces positive interim phase 1 data for its mRNA vaccine (mRNA-1273) against novel coronavirus","year":"2020"},{"key":"10.1016\/j.jiph.2020.07.004_bib0415","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2020.07.004_bib0420","article-title":"First clinical study using HCV protease inhibitor danoprevir to treat naive and experienced COVID-19 patients","author":"Chen HY","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.jiph.2020.07.004_bib0425","article-title":"Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study","author":"Zhang HL","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.jiph.2020.07.004_bib0430","article-title":"Clinical outcomes and plasma concentrations of Baloxavir Marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial","author":"Lou Y","year":"2020","journal-title":"medRxiv"},{"issue":"10","key":"10.1016\/j.jiph.2020.07.004_bib0435","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40265-018-0934-2","article-title":"Darunavir\/Cobicistat\/Emtricitabine\/Tenofovir alafenamide: a review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2020.07.004_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2020.03.032","article-title":"Lopinavir\/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan","author":"Cheng","year":"2020","journal-title":"J Microbiol Immunol Infect"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120305700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120305700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:08:46Z","timestamp":1761750526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034120305700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1876034120305700"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2020.07.004","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2020.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}